Condition: Hereditary Hemorrhagic Telangiectasia · Rendu Osler Disease · Sponsor: University Hospital, Clermont-Ferrand
The goal of this clinical trial is to evaluate in real life, in patients with Hereditary Hemorrhagic Telangiectasia (HHT), the tolerance of the strategy of use of anticoagulant and/or antiplatelet, by comparing a new exposure period (first trimester of treatment) to a period of reference non-exposure (last trimester before start of treatment).
This description comes directly from the study's public registry record.
Lise Laclautre · 334.73.754.963 · promo_interne_drci@chu-clermontferrand.fr
Always discuss trial participation with your own doctor first.
| CHU d'Angers | Angers, France | Recruiting |
| CHU de Bordeaux | Bordeaux, France | Recruiting |
| Hôpital Ambroise Paré | Boulogne-Billancourt, France | Not Yet Recruiting |
| CHU de Caen Normandie | Caen, France | Recruiting |
| CHU clermont-ferrand | Clermont-Ferrand, France | Recruiting |
| CHU de Dijon | Dijon, France | Recruiting |
| CHRU de Lille | Lille, France | Not Yet Recruiting |
| Hospices Civiles de Lyon | Lyon, France | Recruiting |
| Assistance Publique - Hôpitaux de Marseille | Marseille, France | Not Yet Recruiting |
| CHU de Montpellier | Montpellier, France | Recruiting |
| CHU de Nancy | Nancy, France | Recruiting |
| CHU de Nantes | Nantes, France | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05641142